Mizuho's Jared Holz on Novo Nordisk: There's not much upside near-term

Mizuho's Jared Holz on Novo Nordisk: There's not much upside near-termПодробнее

Novo Nordisk falls after strong Q1 results, Mizuho's Jared Holz talks what's next for the companyПодробнее

Mizuho's Holz on weight loss drugs: Lilly and Novo Nordisk are in excellent shape fundamentallyПодробнее

Obesity drug supply-demand imbalance is working in Novo Nordisk's favor: Mizuho's Jared HolzПодробнее

Mounjaro remains the single largest driver for Eli Lilly stock in the near term: Mizuho's Jared HolzПодробнее

Zealand's obesity drug shouldn't disrupt Novo Nordisk-Eli Lilly leadership: Mizuho's Jared HolzПодробнее

Eli Lilly and Novo Nordisk will remain leaders in the weight-loss drug market: Mizuho's Jared HolzПодробнее

It doesn't seem like there's too much momentum for healthcare stocks, says Mizuho's Jared HolzПодробнее

Amgen has 'a lot to prove' in the weight-loss drug category, says Mizuho's Jared HolzПодробнее

Mizuho's Jared Holz on finding opportunities in the biotech spaceПодробнее

Obesity drug enthusiasm can continue in 2024: Mizuho's Jared HolzПодробнее

Biogen has been an 'uninvestable' stock for awhile, says Mizuho's Jared HolzПодробнее

Novo Nordisk (NYSE:NVO) - ADA 2022 (R&D Call)Подробнее

Novo and Eli Lilly stocks could go higher if they show even better data than we think: Mizuho's HolzПодробнее

Drugs for obesity are a massive market, says Mizuho's Jared HolzПодробнее

Mizuho’s Jared Holz breaks down UnitedHealth's Q1 earningsПодробнее

Weight loss drug market is just beginning to take off, says Mizuho's Jared HolzПодробнее

What Novo Nordisk's Ozempic Success Means for DenmarkПодробнее

How Novo Nordisk's ‘select’ study results could shake up the obesity drug spaceПодробнее

The rest of the market will have to participate to hold the rally, says Virtus' Joe TerranovaПодробнее